
Opinion|Videos|December 11, 2024
Case 2: Low-Volume Recurrent mCSPC
Panelists discuss how the management of low-volume recurrent metastatic castration-sensitive prostate cancer (mCSPC) focuses on personalized treatment strategies, including the use of androgen deprivation therapy and targeted therapies, to achieve optimal outcomes while minimizing treatment-related toxicity.
Advertisement
Episodes in this series
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
2
FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent
3
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
4
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
5






